http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018053080-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ce7e5ae3b93c05abe32afc08089aabe |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C259-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-21 |
| filingDate | 2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b87641e031cf42cd195709e09c79979 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4bf95769d7be1f655411916dcf61585 |
| publicationDate | 2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018053080-A1 |
| titleOfInvention | Anti-histone therapy in acute kidney injury |
| abstract | Acute kidney injury (AKI) is often associated with damage to remote organs, such as lungs or heart. AKI induces kidney tubular necrosis as well as NETosis, programmed neutrophil death leading to neutrophil extracellular traps (NETs). Histones released during NETosis induces further formation of NETs, which is damaging to renal tissues and remote organs. Circulating trap-forming neutrophils directly injured the lung, while other dead tissue releases contributed to injury in other organs. Suppressing renal necroinflammation using inhibitors of NET formation, tubular cell necrosis or extracellular histones prevented kidney as well as remote organ injuries. Dual inhibition of neutrophil trap formation together with tubular cell necrosis had an additive protective effect. Preferably, damage to remote organs induced by AKI may be treated and/or prevented using anti-histone agents such as anti-histone IgG, recombinant activated protein C, or heparin, alone or in combination with other therapeutic agents, such as PAD inhibitors. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113122538-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020225549-A1 |
| priorityDate | 2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1852.